Core Points - The document outlines the investment management measures of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd to standardize external investment management, enhance compliance efficiency, and reduce investment risks [1][2] - The investment is defined as the company's allocation of funds, equity, land use rights, or other assessed assets for future returns [1] - Investments are categorized into short-term and long-term based on their duration, with specific definitions provided for each type [1][3] Investment Approval Process - The investment approval must adhere to the Company Law, Shanghai Stock Exchange rules, and the company's articles of association [3][4] - The company implements a professional management and hierarchical approval system for external investments [2][3] Decision-Making Bodies - The shareholders' meeting and the board of directors serve as the decision-making bodies for external investments [3][6] - Certain investment transactions require board approval and must be submitted to the shareholders' meeting if they meet specified thresholds [5][6] Investment Principles - Investments must comply with national laws, align with national industrial policies and the company's development strategy, and not adversely affect the company's main business [4][5] Short-term Investment Procedures - The financial management center provides a cash flow statement and identifies suitable short-term investment opportunities [9][10] - A strict joint control system is required for securities investments, ensuring that at least two personnel are involved in operations [9][10] Long-term Investment Management - Long-term investments are managed by the board office, with other departments participating in the preparation of investment plans [11][12] - Contracts for long-term investments must be reviewed by the company's legal counsel before signing [11][12] Investment Transfer and Recovery - The company can recover investments under specific circumstances, such as project completion or inability to repay debts [26][27] - Investment transfers must comply with the Company Law and the company's articles of association [28][29] Financial Management and Auditing - The financial management center is responsible for comprehensive financial records of investment activities and must conduct annual checks on investments [34][35] - Subsidiaries must report financial statements monthly to ensure compliance with the company's financial policies [38][39] Information Disclosure - The company must fulfill its information disclosure obligations according to relevant laws and regulations [41][42] - Subsidiaries are required to provide accurate and timely information to the company for external disclosure [43][44]

杭州天目山药业股份有限公司重大信息内部报告制度 杭州天目山药业股份有限公司 重大信息内部报告制度 杭州天目山药业股份有限公司重大信息内部报告制度 （2025 年 8 月修订） 第一章 总 则 第一条 为规范杭州天目山药业股份有限公司(以下简称"本公司"或 "公司")的重大信息内部报告工作，保证公司内部重大信息的快速传 递、归集和有效管理，及时、准确、全面、完整地披露信息，维护投资者 的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司信息披露管理办法》《上海证券交易所股票上市规则》(以下简 称"《股票上市规则》"）、《杭州天目山药业股份有限公司章程》（以 下简称"《公司章程》"）、《公司信息披露事务管理制度》等有关规 定，结合本公司实际，制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可 能对公司股票及其衍生品种交易价格产生较大影响的情形或事件时，按照 本制度规定负有报告义务的有关人员和公司，应当在第一时间将相关信息 向董事长和董事会秘书报告并告知董事会办公室的制度。 第三条 本制度所称"内部信息报告义务人"系指按照本制度规定负 有报告义务的有关人员或公司，包括 ...

Core Viewpoint - The article outlines the insider information management system of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd., emphasizing the importance of confidentiality and compliance with relevant laws and regulations in managing insider information [1][2]. Group 1: Insider Information Definition and Scope - Insider information is defined as unpublicized information that significantly impacts the company's operations, finances, or stock market prices, as per the Securities Law [2][3]. - Examples of insider information include shareholder and board resolutions, financial reports, major investments, significant changes in business operations, and any legal or regulatory investigations [2][3][4]. Group 2: Insider Information Knowledge Personnel - Insider information knowledge personnel include company directors, senior management, shareholders holding over 5% of shares, and other individuals or entities that acquire insider information through their duties [4][5]. - The company is required to maintain a complete record of all insider information knowledge personnel, including their details and the timeline of their knowledge [5][6]. Group 3: Confidentiality and Management - Insider information must not be disclosed externally before it is publicly announced, and knowledge should be limited to the smallest possible group [6][7]. - External parties receiving insider information must be informed of their confidentiality obligations and the information must be clearly marked as "insider information" [7][8]. Group 4: Accountability and Penalties - The company will impose administrative and financial penalties on insider information knowledge personnel who leak information or engage in insider trading that causes significant harm to the company [9][10]. - Violations of laws and regulations regarding insider information may lead to criminal charges and referral to judicial authorities [10][11].

Core Points - The document outlines the information disclosure deferral and exemption management system for Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd, aiming to ensure compliance with legal obligations and protect investors' rights [1][2][3] Group 1: Information Disclosure Management - The company must adhere to various laws and regulations, including the Company Law and Securities Law, while managing information disclosure deferrals and exemptions [1] - Information that involves state secrets or commercial secrets must not be disclosed through any means, including investor interactions and press releases [2][3] - The company can defer or exempt disclosure of information that may lead to unfair competition or harm to its interests or those of others [3][4] Group 2: Conditions for Disclosure Deferral - If the reasons for deferral or exemption are no longer valid, or if the information becomes difficult to keep confidential, timely disclosure is required [5][6] - The definition of commercial secrets includes information that is not publicly known, provides economic benefits, and is protected by confidentiality measures [6][7] Group 3: Internal Review Procedures - A formal internal review process is required for deferring or exempting information disclosure, involving the board secretary and the company chairman [5][6] - The company must maintain records of all deferral and exemption requests for a minimum of 10 years [6] Group 4: Reporting Obligations - After the announcement of annual, semi-annual, or quarterly reports, the company must submit relevant documentation regarding deferred or exempted disclosures to the Zhejiang Securities Regulatory Bureau and the Shanghai Stock Exchange within ten days [6][7] - Any amendments to the system must comply with the latest laws and regulations, and the board is responsible for its formulation and revision [7]

杭州天目山药业股份有限公司防范大股东及其关联方资金占用制度 杭州天目山药业股份有限公司 防范大股东及其关联方资金占用专项制度 （2025年8月修订） 第一章 总则 第一条 为了防止大股东、控股股东或实际控制人及其关联方（以 下简称"大股东及其关联方"）占用杭州天目山药业股份有限公司 （以下简称"公司"）资金，建立防范的长效机制，杜绝大股东及其 关联方资金占用行为的发生，维护公司的独立性，根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》《上市公司自律监管指引第8号——上市公司资金往来、对外担保 的监管要求》《上市公司治理准则》、《上海证券交易所股票上市规 则》（以下简称"《股票上市规则》"）、《上海证券交易所上市公 司自律监管指引第1号——规范运作》（以下简称"《规范运作》"） 和《杭州天目山药业股份有限公司章程》（以下简称"《公司章 程》"）以及国家规定的相关法律、法规和规范性文件的有关规定， 制定本制度。 第二条 公司董事和高级管理人员对维护公司资金安全有法定义务。 第三条 本制度所称资金占用包括但不限于：经营性资金占用和非 经营性资金占用。经营性资金占用是指大股东及其关 ...

Core Viewpoint - The document outlines the responsibilities, qualifications, and operational procedures for the Secretary of the Board of Directors at Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd, emphasizing the importance of compliance with relevant laws and regulations [1][2][3]. Summary by Sections General Principles - The Secretary of the Board is a senior management position responsible for the company and the board, acting as a liaison with the stock exchange [1]. - The role is defined by the Company Law, Securities Law, and relevant stock exchange rules [1]. Qualifications - Candidates for the Secretary position must possess good professional ethics, necessary financial, management, and legal knowledge, and relevant work experience [2]. - Certain individuals are disqualified from serving as Secretary, including those with recent administrative penalties from the China Securities Regulatory Commission [2] [3]. Responsibilities - The Secretary is responsible for information disclosure, investor relations management, and organizing board and shareholder meetings [3][4]. - The role includes ensuring compliance with legal and regulatory requirements, managing stock and derivative transactions, and facilitating communication between the company and various stakeholders [3][4][5]. Appointment and Dismissal - The Secretary is nominated by the Chairman and appointed by the Board, with a requirement to report to the stock exchange within five trading days of the appointment [6][7]. - Grounds for dismissal include failure to perform duties, legal violations, or causing significant losses to the company [8]. Transitional Provisions - In the event of a vacancy, the Chairman will temporarily assume the Secretary's duties until a new appointment is made within six months [9]. - The document stipulates that any unresolved obligations must be completed by the outgoing Secretary before departure [8][9].

Core Viewpoint - The document outlines the information disclosure management system of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of the company and its investors [1][2]. Group 1: General Principles - The information disclosure obligations must be fulfilled timely and should be true, accurate, complete, and fair, avoiding any false records or misleading statements [2][3]. - The system applies to various personnel including the board of directors, senior management, and major shareholders [2][3]. - The company must ensure that all disclosed information is made available to all investors simultaneously, without any selective disclosure [4][5]. Group 2: Disclosure Content - The company is required to disclose periodic reports, including annual, semi-annual, and quarterly reports, as well as other significant documents like prospectuses and acquisition reports [6][7]. - Annual reports must be disclosed within four months after the fiscal year-end, while semi-annual reports should be disclosed within two months after the first half of the fiscal year [7][8]. - The content of the annual report includes basic company information, major financial data, stock and bond issuance details, and significant events affecting the company [8][9]. Group 3: Responsibilities and Management - The board of directors is responsible for overseeing the information disclosure process, with the chairman being the primary responsible person [17][18]. - The board secretary plays a crucial role in coordinating the information disclosure activities and ensuring compliance with relevant regulations [17][18]. - All departments and subsidiaries must report significant information to the board secretary promptly to ensure timely disclosure [21][22]. Group 4: Compliance and Training - The company must provide training on information disclosure responsibilities to relevant personnel to ensure compliance with regulations [25][26]. - Any violations of the disclosure obligations may lead to administrative and economic penalties for responsible individuals [26][27]. - The company must maintain communication with regulatory bodies and ensure that all disclosures are in line with legal requirements [25][28].

Core Viewpoint - The article outlines the working rules and responsibilities of the Strategic Committee of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd., emphasizing the importance of enhancing corporate governance and decision-making processes for long-term strategic development [1][2]. Group 1: General Provisions - The Strategic Committee is established to improve corporate governance and ensure the rationality of long-term development strategies and plans [1]. - The committee is accountable to the Board of Directors and operates under the guidelines of the company's articles of association and relevant regulations [1][2]. Group 2: Composition - The committee consists of 3 to 5 directors, including at least one expert in management, law, or product development [2]. - The committee members are nominated by the chairman or independent directors and elected by the Board [2]. Group 3: Responsibilities and Authority - The main responsibilities include researching long-term development strategies, major investments, sustainable development, and ESG governance [4]. - The committee evaluates internal and external environmental changes affecting the company's strategic position and market strategies [4]. - It also reviews major investment and financing plans, assesses significant ESG matters, and guides subsidiaries in implementing strategic and risk management policies [4][5]. Group 4: Work Procedures - The committee operates as a non-full-time body, conducting regular and ad-hoc meetings as needed [5]. - Relevant departments are responsible for providing timely and accurate information to support the committee's work [5][6]. Group 5: Meeting Rules - Meetings require the presence of at least two-thirds of the members to be valid, and decisions are made by a majority vote [6][7]. - The committee can invite external experts for professional opinions, with costs covered by the company [7][8].

第一条 为进一步完善杭州天目山药业股份有限公司（以下简称 "公司"）的法人治理结构，规范独立董事行为，充分发挥独立董事 在上市公司治理中的作用，促进提高上市公司质量，维护公司的整体 利益及中小投资者的合法利益，根据《中华人民共和国公司法》《中 华人民共和国证券法》《国务院办公厅关于上市公司独立董事制度改 革的意见》 《上市公司独立董事管理办法》 《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等法律、法规及规范性文件及《杭 州天目山药业股份有限公司章程》 （以下简称" 《公司章程》" ）有关规 杭州天目山药业股份有限公司独立董事制度 杭州天目山药业股份有限公司 独立董事制度 （2025 年 8 月修订） 第一章 总 则 定，结合公司实际情况，特制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与 其所受聘的公司及其主要股东、实际控制人不存在直接或者间接利害 关系，或者其他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制 人等单位或者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当 按照法律、行政法规、中国证券 ...

杭州天目山药业股份有限公司董事会薪酬与考核委员会工作细则 杭州天目山药业股份有限公司 董事会薪酬与考核委员会工作细则 （2025 年 8 月修订） 第一章 总则 第一条 为进一步建立健全杭州天目山药业股份有限公司（以下 简称"公司"）董事及高级管理人员的考核和薪酬管理制度，完善公 司治理结构，根据《中华人民共和国公司法》《上市公司治理准则》 《杭州天目山药业股份有限公司公司章程》 （以下简称" 《公司章程》 "） 及有关规定，公司特设立董事会薪酬与考核委员会，并制定本工作细 则。 第二条 薪酬与考核委员会是董事会设立的专门工作机构，主要 负责制定公司董事及高级管理人员的考核标准并进行考核；负责制 定、审查公司董事及高级管理人员的薪酬政策与方案，对董事会负责。 第三条 本细则所称董事是指在本公司领取薪酬的董事长、董事， 高级管理人员是指董事会聘任的总经理、副总经理、董事会秘书、财 务总监及《公司章程》中规定的高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由三名董事组成，独立董事占多 数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董 事或者全体董事的三分之一提名，并由董事会选举产生。 ...